文献速递胸部肿瘤放疗

不可手术III期非小细胞肺癌诱导化疗免疫治疗后同步放化疗与单纯放疗比较:单中心回顾性研究

Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
PubMed 文献 · Radiat Oncol · 2023-07-25

该单中心回顾性研究纳入2018年11月至2021年12月天津肿瘤医院65例接受诱导化疗免疫治疗后未手术的III期非小细胞肺癌患者,44例(67.7%)接受单纯放疗,21例(32.3%)接受同步放化疗。同步放化疗组无进展生存期(HR=0.155,p=0.004)、局部无进展生存期(HR=0.225,p=0.029)和无远处转移生存期(HR=0.028,p=0.006)均显著优于单纯放疗组,总生存期有改善趋势但未达统计学显著(HR=0.030,p=0.069)。两组治疗相关不良事件相似(p>0.05)。

要点

  • 同步放化疗组较单纯放疗组显著延长无进展生存期(HR=0.155,p=0.004)。
  • 同步放化疗组局部无进展生存期(HR=0.225,p=0.029)和无远处转移生存期(HR=0.028,p=0.006)均显著优于单纯放疗组。
  • 总生存期改善趋势未达统计学显著(HR=0.030,p=0.069),两组不良事件相似(p>0.05)。

核心结论

  • 对于不可切除的III期非小细胞肺癌患者,化疗免疫治疗后行同步放化疗似乎安全,且与单纯放疗相比可能延长生存。
  • 作者认为有必要进一步研究化疗免疫治疗与同步放化疗的联合应用。

研究设计与样本

  • 单中心回顾性研究,纳入2018年11月至2021年12月天津肿瘤医院诊断为III期非小细胞肺癌、接受化疗免疫治疗后行同步放化疗或单纯放疗且未手术的患者。
  • 共纳入65例患者,其中44例(67.7%)接受单纯放疗,21例(32.3%)接受同步放化疗。
  • 采用Kaplan-Meier法估计生存,采用单因素和多因素Cox回归模型评估无进展生存期的危险因素。

主要发现

  • 同步放化疗组较单纯放疗组显著延长无进展生存期(HR=0.155,p=0.004)。
  • 同步放化疗组较单纯放疗组显著延长局部无进展生存期(HR=0.225,p=0.029)。
  • 同步放化疗组较单纯放疗组显著延长无远处转移生存期(HR=0.028,p=0.006)。
  • 同步放化疗组较单纯放疗组总生存期有改善趋势但未达统计学显著(HR=0.030,p=0.069)。
  • 多因素分析进一步证实同步放化疗是无进展生存期改善的独立因素(HR=0.141,p=0.008);两组治疗相关不良事件相似(p>0.05)。

关键数值与推荐

  • 同步放化疗组较单纯放疗组无进展生存期HR=0.155(p=0.004)。
  • 同步放化疗组较单纯放疗组局部无进展生存期HR=0.225(p=0.029)。
  • 同步放化疗组较单纯放疗组无远处转移生存期HR=0.028(p=0.006)。
  • 同步放化疗组较单纯放疗组总生存期HR=0.030(p=0.069),未达统计学显著。
  • 多因素分析中同步放化疗对无进展生存期的HR=0.141(p=0.008);两组治疗相关不良事件比较p>0.05。

临床怎么用

  • 对于不可切除的III期非小细胞肺癌患者,化疗免疫治疗后行同步放化疗似乎安全,且与单纯放疗相比可能延长生存。
  • 作者认为有必要进一步研究化疗免疫治疗与同步放化疗的联合应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With remarkable success and few side effects, induction chemoimmunotherapy has been used to improve the prognosis of patients with resectable or potentially resectable non-small cell lung cancer (NSCLC), even in stage III disease. However, for patients who are medically inoperable, unresectable or refuse surgery after induction chemoimmunotherapy, it is unclear whether patients should be treated with concurrent chemoradiotherapy (cCRT) or radiotherapy (RT) alone considering patient safety and tolerability. This study aimed to determine whether cCRT is safe and superior to RT alone after chemoimmunotherapy for stage III NSCLC. METHODS: Patients diagnosed with stage III NSCLC who received chemoimmunotherapy followed by cCRT/RT alone without surgery at Tianjin Cancer Hospital between November 2018 to December 2021 were retrospectively collected. Patients were divided into two groups: induction chemoimmunotherapy followed by cCRT (cCRT cohort) or RT alone (RT alone cohort). Kaplan-Meier method was used to estimate survival. Univariate and multivariate Cox regression models were adopted to estimate risk factors for PFS. RESULTS: Sixty-five patients were included, with 44 (67.7%) received RT alone and 21 (32.3%) received cCRT. Patients in the cCRT group had significantly prolonged PFS (HR = 0.155, p = 0.004), LPFS (HR = 0.225, p = 0.029) and DMFS (HR = 0.028, p = 0.006) than those in the RT alone group. Albeit nonsignificant, a trend toward improved OS (HR = 0.030, p = 0.069) was also observed in the cCRT group. The multivariate analysis further confirmed that cCRT (HR = 0.141, p = 0.008) was the independent factor for promoting a favorable PFS. Treatment-related adverse events were similar between groups (p > 0.05). Patients with consolidation immunotherapy exhibited a trend of improved PFS (HR = 0.398, p = 0.274) and numerically better OS (HR = 0.018, p = 0.209) compared with those without. CONCLUSIONS: For patients with unresectable stage III NSCLC, cCRT following chemoimmunotherapy appears to be safe and may prolong survival compared with radiotherapy alone. Further investigations on the combination of chemoimmunotherapy and CRT are warranted.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Guan S, Ren K, Zhang X, et al. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study. Radiat Oncol. 2023. PMID: 37491257. doi:10.1186/s13014-023-02305-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。